Comparative Pharmacology
Head-to-head clinical analysis: DERMA SMOOTHE FS versus ELDECORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMA SMOOTHE FS versus ELDECORT.
DERMA-SMOOTHE/FS vs ELDECORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
Corticosteroid binding to glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects via inhibition of phospholipase A2, reduction of prostaglandins and leukotrienes, and modulation of cytokine production.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
Initial: 5-60 mg orally once daily, adjusted based on response; typical maintenance: 5-15 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Terminal elimination half-life is 3.5 ± 1.2 hours in adults with normal renal function; prolonged to 6–8 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Renal excretion of unchanged drug accounts for approximately 60% of the dose; fecal elimination contributes about 30% due to biliary secretion; the remaining 10% is metabolized.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid